Quick Answer
Evofem Biosciences, Inc. reported Total Revenue of $19.36 million for fiscal year 2024.
Evofem Biosciences, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $19.36M +6.3% |
$18.22M +8.2% |
$16.84M +104.2% |
$8.24M +1748.4% |
$446.0K | $0.00 |
| Revenue (ASC 606) | $19.36M +6.3% |
$18.22M +8.2% |
$16.84M | — | — | — |
| Net Income | -$8.86M -116.7% |
$52.98M +169.1% |
-$76.70M +62.6% |
-$205.19M -44.2% |
-$142.31M -77.8% |
-$80.03M +36.3% |
| Diluted EPS | -$0.12 -340.0% |
$0.05 +100.0% |
-$167.42 -608.5% |
-$23.63 -1014.6% |
-$2.12 | — |
| Total Assets | $23.79M +125.4% |
$10.55M -58.1% |
$25.16M -40.8% |
$42.51M -61.3% |
$109.97M +288.6% |
$28.30M +605.6% |
| Cash and Equivalents | — | — | $2.77M -64.2% |
$7.73M -84.2% |
$48.89M +214.0% |
$15.57M +1070.8% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | -$71.26M -7.1% |
-$66.51M +7.4% |
-$71.80M +31.2% |
-$104.31M -7844.2% |
$1.35M -91.4% |
$15.64M +166.9% |
| R&D Expense | $1.84M -37.2% |
$2.94M -88.3% |
$25.03M -24.4% |
$33.13M +94.3% |
$17.05M -23.3% |
$22.23M -48.8% |
| Operating Income | -$7.68M +57.0% |
-$17.85M +78.8% |
-$84.12M +49.6% |
-$166.80M -61.0% |
-$103.62M -96.5% |
-$52.74M +32.1% |
| Shares Outstanding | 113.36M +466.6% |
20.01M +1931.7% |
984,786 -90.9% |
10.83M -86.7% |
81.35M +69.0% |
48.14M +86.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $4.95M | +10.1% | +2.6% |
| Revenue (ASC 606) | September 30, 2025 | $4.95M | +10.1% | +2.6% |
| Net Income | September 30, 2025 | -$1.57M | +33.7% | +12.1% |
| Diluted EPS | September 30, 2025 | -$0.01 | +50.0% | +50.0% |
| Total Assets | September 30, 2025 | $13.81M | -42.3% | -4.0% |
| Cash and Equivalents | March 31, 2025 | $221.0K | — | -65.4% |
| Long-Term Debt | June 30, 2016 | $2.81M | -67.4% | -10.9% |
| Stockholders Equity | September 30, 2025 | -$75.07M | -5.9% | -7.8% |
| R&D Expense | September 30, 2024 | $332.0K | -45.9% | +23.0% |
| Operating Income | September 30, 2025 | $951.0K | +139.0% | +176.0% |
| Shares Outstanding | September 30, 2025 | 123.96M | +23.6% | +4.5% |
- Evofem Biosciences, Inc. reported Total Revenue of $19.36 million for fiscal year 2024.
- Evofem Biosciences, Inc. showed an increase of +6.3% in Total Revenue compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported Revenue (ASC 606) of $19.36 million for fiscal year 2024.
- Evofem Biosciences, Inc. showed an increase of +6.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported Net Income of -$8.86 million for fiscal year 2024.
- Evofem Biosciences, Inc. showed a decrease of -116.7% in Net Income compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported Diluted EPS of $0.12 per share (loss) for fiscal year 2024.
- Evofem Biosciences, Inc. showed a decrease of -340.0% in Diluted EPS compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported Total Assets of $23.79 million for fiscal year 2024.
- Evofem Biosciences, Inc. showed an increase of +125.4% in Total Assets compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported Cash and Equivalents of $2.77 million for fiscal year 2022.
- Evofem Biosciences, Inc. showed a decrease of -64.2% in Cash and Equivalents compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported Long-Term Debt of $7.21 million for fiscal year 2015.
- Evofem Biosciences, Inc. showed a decrease of -26.0% in Long-Term Debt compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported Stockholders Equity of -$71.26 million for fiscal year 2024.
- Evofem Biosciences, Inc. showed a decrease of -7.1% in Stockholders Equity compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported R&D Expense of $1.84 million for fiscal year 2024.
- Evofem Biosciences, Inc. showed a decrease of -37.2% in R&D Expense compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported Operating Income of -$7.68 million for fiscal year 2024.
- Evofem Biosciences, Inc. showed an increase of +57.0% in Operating Income compared to the prior fiscal year.
- Evofem Biosciences, Inc. reported Shares Outstanding of 113.36 million shares for fiscal year 2024.
- Evofem Biosciences, Inc. showed an increase of +466.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: